| Omidenepag isopropyl | 520.61
C26H28N6O4S |  | An agonist of the prostaglandin EP2 receptor indicated for the reduction of elevated intraocular pressure. | Antiglaucoma Agents / Hypotensive Agents / Ophthalmic Solutions / Ophthalmics / Prodrugs / Pyrazoles / Pyridines / Receptors, Prostaglandin E, EP2 Subtype, agonists / Sulfonamides |
| Aprocitentan | 546.19
C16H14Br2N6O4S |  | An endothelin receptor antagonist used for the treatment of uncontrolled hypertension in patients inadequately controlled on other treatments. | Amides / BCRP/ABCG2 Inhibitors / BCRP/ABCG2 Substrates / BSEP/ABCB11 Inhibitors / Cytochrome P-450 CYP2C18 Inhibitors / Cytochrome P-450 CYP2C18 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C19 Inhibitors / Cytochrome P-450 CYP2C19 inhibitors (strength unknown) / Cytochrome P-450 CYP2C8 Inhibitors / Cytochrome P-450 CYP2C8 Inhibitors (strength unknown) / Cytochrome P-450 CYP2C9 Inhibitors / Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Enzyme Inhibitors / Endothelin Receptor Antagonists / P-glycoprotein substrates / Sulfones / Sulfur Compounds / UGT1A1 Inhibitors / UGT1A1 Substrates / UGT2B7 Inhibitors / UGT2B7 substrates |
| Zanubrutinib | 471.561
C27H29N5O3 |  | A kinase inhibitor used to treat mantle cell lymphoma, a type of B-cell non-Hodgkin lymphoma, in adults who previously received therapy. | Bruton's tyrosine kinase (BTK) inhibitors / Tyrosine Kinase Inhibitors |
| Daridorexant | 450.93
C23H23ClN6O2 |  | A dual orexin receptor antagonist used to treat insomnia in adults. | Orexin Receptor Antagonists |
| Avacopan | 581.656
C33H35F4N3O2 |  | An orally bioavailable complement 5a receptor (C5aR) antagonist for the treatment of severe anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis. | Selective Immunosuppressants |
| Umbralisib | 571.56
C31H24F3N5O3 |  | A kinase inhibitor used to treat rare forms of refractory lymphoma. | Kinase Inhibitor |
| Voxelotor | 337.379
C19H19N3O3 |  | A drug used to inhibit the polymerization of hemoglobin S, preventing the painful and sometimes lethal vaso-occlusive crises associated with sickle cell disease. | Hematologic Agents |
| Abrocitinib | 323.42
C14H21N5O2S |  | A kinase inhibitor used to treat moderate-to-severe atopic dermatitis in adults. | Agents for Dermatitis, Excluding Corticosteroids |
| Ritlecitinib | 285.351
C15H19N5O |  | A kinase inhibitor used to treat severe alopecia areata in adults and adolescents 12 years and older. | Cytochrome P-450 CYP1A2 Inhibitors / Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) / Cytochrome P-450 CYP1A2 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Immunomodulatory Agents / Immunosuppressive Agents / Janus Kinase 3, antagonists & inhibitors / Janus Kinase Inhibitors / Janus Kinases, antagonists & inhibitors |
| Mavacamten | 273.336
C15H19N3O2 |  | A myosin inhibitor used to treat obstructive hypertrophic cardiomyopathy. | Amines / Benzene Derivatives / Benzyl Compounds / Cardiac Myosin Inhibitor / Cardiac Therapy / Cytochrome P-450 CYP2B6 Inducers / Cytochrome P-450 CYP2B6 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Inducers / Cytochrome P-450 CYP2C19 Inducers (strength unknown) / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Inducers / Cytochrome P-450 CYP2C9 Inducers (strength unknown) / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Inducers / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inducers / Cytochrome P-450 CYP3A4 Inducers (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 Enzyme Inducers / Cytochrome P-450 Substrates / Pyrimidines / Pyrimidinones |
| Flortaucipir F-18 | 262.278
C16H10FN3 |  | A small lipophilic tracer containing [18F]fluoride capable of crossing the blood-brain barrier and binding to aggregated tau protein; used in PET imaging for the diagnosis of Alzheimer's disease. | Contrast Media |
| Vibegron | 444.535
C26H28N4O3 |  | A beta-3 adrenergic agonist the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. | Adrenergic Agonists / Adrenergic beta-3 Receptor Agonists / Adrenergic beta-Agonists / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Drugs for Urinary Frequency and Incontinence / Genitourinary Smooth Muscle Relaxants / P-glycoprotein substrates / Pyrimidines / Selective Beta 3-adrenergic Agonists |
| Oliceridine | 386.55
C22H30N2O2S |  | A biased opioid agonist indicated for the management of severe acute pain in adult patients. Through preferential activation of G-protein-coupled signalling pathways, oliceridine provides analgesic effect with a comparable or improved safety profile over conventional opioid agonists. | Ligands |
| Cefiderocol | 752.21
C30H34ClN7O10S2 |  | A cephalosporin antibiotic used in complicated urinary tract infections. | beta Lactam Antibiotics |
| Filgotinib | 425.51
C21H23N5O3S |  | A Janus kinase (JAK) 1 selective inhibitor used to treat cases of rheumatoid arthritis that are unresponsive to conventional treatments. | Selective Immunosuppressants |
| Ripretinib | 510.367
C24H21BrFN5O2 |  | A kinase inhibitor used to treat advanced gastrointestinal stromal tumor (GIST). | Kinase Inhibitor |
| Piflufolastat F 18 | 441.403
C18H23FN4O8 |  | A radiopharmaceutical diagnostic agent used with PET to image PSMA-positive lesions for the diagnosis of metastatic or recurrent prostate cancer. | Fluorine Radioisotopes / Radioactive Diagnostic Agent |
| Diroximel fumarate | 255.226
C11H13NO6 |  | A drug used for the treatment of relapsing forms of Multiple Sclerosis (MS). | Acids, Acyclic / Antineoplastic and Immunomodulating Agents / Dicarboxylic Acids / Fumarates / Hepatotoxic Agents / Immunosuppressive Agents |
| Etrasimod | 457.493
C26H26F3NO3 |  | An S1P receptors modulator used to treat moderate to severely active ulcerative colitis in adults | Acids, Acyclic / Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Substrates / Fatty Acids / Fatty Acids, Volatile / Heterocyclic Compounds, Fused-Ring / Lipids |
| Cycloguanil | 251.715
C11H14ClN5 |  | Cycloguanil is the active metabolite of proguanil. | Biguanides |
| Remdesivir | 602.585
C27H35N6O8P |  | A nucleoside analog used to treat RNA virus infections including COVID-19. | Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors |
| Solriamfetol | 194.234
C10H14N2O2 |  | Solriamfetol is indicated for treatment of daytime sleepiness associated with obstructive sleep apnea and narcolepsy, but is not a treatment for the underlying airway obstruction in apnea patients[FDA Label][A176534,A176744]. | Centrally Acting Sympathomimetics |
| Hydroxystilbamidine | 280.331
C16H16N4O |  | Used in the treatment of nonprogressive blastomycosis of the skin and other mycoses. | Amidines / Benzene Derivatives / Benzylidene Compounds / Stilbenes |
| Racephedrine | 165.236
C10H15NO |  | Not Annotated | Adrenergic Agonists / Adrenergic alpha-Agonists / Adrenergic beta-Agonists / Alpha-and Beta-adrenergic Agonists / Herbs and Natural Products / Norepinephrine Releasing Agents / Sympathomimetic (Adrenergic) Agents |
| Ceftobiprole medocaril | 690.66
C26H26N8O11S2 |  | A broad spectrum 5th-generation cephalosporin antibacterial indicated for certain kinds of pneumonia, bacteremia, and skin and skin structure infections, including those caused by MRSA. | Anti-Bacterial Agents |
